BrainParrot

PLI Scheme for Medical Devices extended up to 2035–36; Fresh applications invited

GS3Full notePublished: · Updated:

Source: PIB (Press Information Bureau) · Read the original ↗

Summary

  • The Department of Pharmaceuticals has opened a fresh round of applications under the PLI scheme for domestic medical-device manufacturing (PLI-MD). The scheme is now extended to 2035–36.
  • About ₹2,700 crore of outlay is available for this round. Applications go through an online portal due to go live within 10 days.
  • The release calls the new phase "PLI-MD 2.0". Eligibility and claim procedures have been simplified based on lessons from the first phase.

UPSC relevance: GS3 Economy — industrial policy, manufacturing, import substitution; GS2 — health

Key facts for Prelims

  • PLI-MD is run by the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers).
  • Four Target Segments in the new phase:
  • TS1: medical consumables, disposables and implants.
  • TS2: critical components.
  • TS3: high-end devices at a nascent stage of domestic manufacturing.
  • TS4: high-end devices that are currently only assembled in India.
  • Time allowed to set up manufacturing facilities: 3 years.
  • Incentive is tapering, not flat. It averages ~5% for TS1, ~9% for TS2 and TS3, and 6% for TS4.
  • Scheme launched in 2020–21; now extended up to 2035–36.
  • Applications are submitted online; the application window stays open continuously over a long period.
  • Devices named as already made domestically under the scheme: X-ray tubes and detectors, 1.5T MRI, LINAC, CT scanners, mammography machines, Cath lab, orthopaedic and cardiac implants, dialyzers.
  • Devices the scheme now targets that India does not yet make: 3T MRI, PET-CT, ultrasound probes and consoles, high-throughput IVD analyzers.

Data and details

  • Outlay available for this round: about ₹2,700 crore.
  • Portal to be operational within the next 10 days.
  • First phase results: over 60 high-end devices and components made domestically. Production is valued at over ₹16,000 crore.
  • Average tapering incentive rates: ~5% (TS1), ~9% (TS2 and TS3), 6% (TS4).
  • Simplifications:
  • The minimum sales threshold for claiming incentive is discontinued.
  • The minimum investment requirement is trimmed.
  • Applicants may file any number of applications across one or more TS.
  • Focus areas per segment:
  • Consumables and disposables: manufacturing scale and world-class quality.
  • TS3 and TS4: value-chain integration for competitiveness and quality.
  • Critical components: value-chain integration plus a boost to MSMEs.
  • Stated aims of PLI-MD 2.0: Atmanirbhar Bharat/Make in India, indigenous supply chains, investment, employment, better quality, lower device prices and global competitiveness in high-end medtech.

Static–dynamic linkage

A Production Linked Incentive (PLI) scheme pays firms a cash incentive on sales of goods made in India, usually incremental sales over a base year. It differs from an input subsidy or a duty wall because the incentive is paid only after output happens. The aim is to build scale, absorb the cost disadvantages of Indian manufacturing and cut import dependence. In medical devices the usual disadvantages are weak component ecosystems, high cost of finance and thin R&D. PLI-MD is a sector application of the Atmanirbhar Bharat / Make in India approach. The 2026 change shows a design shift from sales-linked entry hurdles towards value-chain depth and a continuously open application window.

Syllabus mapping: GS3 – Economy: Industrial policy, manufacturing, investment models, Atmanirbhar Bharat; GS2 – Health (domestic availability and affordability of medical technology)

Background primer

PLI Scheme for Promoting Domestic Manufacturing of Medical Devices (PLI-MD)

What it is:
A Department of Pharmaceuticals scheme giving financial incentives on sales of medical devices manufactured in India. The original scheme paid selected companies 5% of incremental sales of devices made in India. The incentive ran for five years.
Founded:
Launched in 2020–21 (per the article). The original outlay was ₹3,420 crore. The first round covered four target segments: radiotherapy (cancer care); imaging devices; anaesthesia, cardio-respiratory and critical care devices; and implants.
Members:
Selected applicants (manufacturers, including MSMEs). As of Dec 2024, 32 applicants had been selected and 19 greenfield projects commissioned for 44 products. The scheme is administered by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Mandate:
Create domestic manufacturing capacity, attract investment and incentivise production of devices that were earlier imported.
Why it matters:
Self-reliance (Atmanirbhar Bharat), supply-chain resilience, lower prices and export competitiveness.

Additional context

  • The original scheme had a five-year incentive period running from FY2022–23 to FY2026–27. The 2035–36 extension therefore stretches the horizon well beyond the first phase.
  • The scheme sits within a wider support ecosystem:
    • Three Medical Device Parks are approved at Greater Noida (UP), Ujjain (MP) and Kanchipuram (Tamil Nadu).
    • Their total project cost is ₹871.11 crore, with ₹100 crore of central assistance each for common infrastructure.
    • The National Medical Devices Policy, 2023 provides the holistic policy framework.
    • A ₹500 crore Scheme for Strengthening the Medical Device Industry supports components, skilling and clinical studies.
    • The PRIP scheme for pharma-medtech R&D has a ₹5,000 crore outlay.
  • A Dec 2025 PIB release said devices made under the scheme are about 10–30% cheaper than imported equivalents.

Mains dimensions

  • Why the design changed:
  • Scrapping the minimum sales threshold and trimming minimum investment lowers entry barriers for smaller firms.
  • A continuously open window removes the "one-shot" cliff.
  • These changes follow the first phase's lessons, which the release does not itemise.
  • Value-chain depth over assembly:
  • TS2 (critical components) and the TS3/TS4 split target the "assemble-in-India" trap, where final assembly is local but components are imported.
  • Component focus also links the scheme to MSME growth.
  • Health outcomes: Lower device prices and domestic availability of 3T MRI, PET-CT and IVD analyzers support affordability and diagnostic access. The release lists price reduction as an aim but gives no target.
  • Fiscal and design questions:
  • Round outlay (~₹2,700 crore) is smaller than the original ₹3,420 crore, but the horizon runs to 2035–36.
  • Tapering incentives (~5–9%) rest on a "build scale, then stand alone" logic.
  • The release gives no incentive caps or committed-investment figures for the round.
  • Strategic angle: Reduces import dependence in a sector where imports exceeded 85% of the market in 2020. Builds supply-chain resilience after the pandemic experience.
  • Limits: Output of over ₹16,000 crore is a production figure, not a net import-substitution figure. The release does not say how far import dependence has fallen.

Possible Mains question

**GS3, 15 marks:** "Production Linked Incentive schemes are meant to build manufacturing scale and reduce import dependence. With reference to the medical devices PLI scheme, examine the design changes in its second phase and discuss how far they can deepen domestic value chains."

Related topics

  • PLI schemes across sectors (pharma, bulk drugs, electronics) and the Atmanirbhar Bharat / Make in India framework
  • Scheme for Promotion of Medical Devices Parks; National Medical Devices Policy, 2023
  • MSME policy and the import-substitution vs. export-competitiveness debate
  • Public health infrastructure and affordability of diagnostics (GS2)

Topics: GS3

How we write and check these notes →

All current affairs of 10 November 2026 → · UPSC Current Affairs